高葡萄糖血症
胰高血糖素
胰高血糖素受体
分解代谢
内分泌学
内科学
糖尿病
胰岛素
激素
生物
医学
新陈代谢
作者
Megan E. Capozzi,David A. D’Alessio,Jonathan E. Campbell
出处
期刊:Cell Metabolism
[Elsevier]
日期:2022-11-01
卷期号:34 (11): 1654-1674
被引量:20
标识
DOI:10.1016/j.cmet.2022.10.001
摘要
The evolution of glucagon has seen the transition from an impurity in the preparation of insulin to the development of glucagon receptor agonists for use in type 1 diabetes. In type 2 diabetes, glucagon receptor antagonists have been explored to reduce glycemia thought to be induced by hyperglucagonemia. However, the catabolic actions of glucagon are currently being leveraged to target the rise in obesity that paralleled that of diabetes, bringing the pharmacology of glucagon full circle. During this evolution, the physiological importance of glucagon advanced beyond the control of hepatic glucose production, incorporating critical roles for glucagon to regulate both lipid and amino acid metabolism. Thus, it is unsurprising that the study of glucagon has left several paradoxes that make it difficult to distill this hormone down to a simplified action. Here, we describe the history of glucagon from the past to the present and suggest some direction to the future of this field.
科研通智能强力驱动
Strongly Powered by AbleSci AI